Viatris Inc
Viatris is a global healthcare company headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India. It supplies medicines to approximately 1 billion patients around the world each year and operates in more than 165 countries and territories. Viatris markets branded and generic drugs, including complex medicines, across therapeutic areas such as cardiovascular health, oncology and infectious diseases. Its products include Breyna, Wixela Inhub and generic iron sucrose injection. It also offers patient support services, including diagnostic clinics, educational seminars and digital tools. Viatris sells its products to customers including pharmacies, wholesalers, distributors, governments and hospitals, and enters into licensing and other agreements with pharmaceutical partners. Its four geographic segments are Developed Markets, Emerging Markets, JANZ and Greater China.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $VTRS in the last 30 days.
See all $VTRS insider activity →Viatris (VTRS) and Eli Lilly (LLY) raised 2026 sales forecasts. Lilly increased its revenue forecast to $91.5B, while Viatris raised its forecast to $14.75B. Lilly's growth is driven by Mounjaro and Zepbound, while Viatris focuses on generics and potential blockbuster drugs. Lilly has higher margins and lower debt, but Viatris trades at a lower valuation.
In October 2026, The Pharma Letter reported 12 M&A deals, including four worth over $1 billion. Shionogi (TYO: 4507) acquired IntraBio for $2 billion. Viatris (Nasdaq: VTRS) agreed to buy Pacira BioSciences (Nasdaq: PCRX) for $1.65 billion. Ferring Pharmaceuticals agreed to pay up to $1.38 billion for Gameto. Merck KGaA (ETR: MRK) acquired Silence Therapeutics (Nasdaq: SLN) for about $1.3 billion.
The FDA approved phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) for presbyopia in October 2026. The drug reduces pupil size via a sympatholytic mechanism, avoiding ciliary muscle engagement. Clinical trials showed 27.2% of patients gained near vision without losing distance vision. Experts discuss its unique mechanism and potential patient benefits compared to other presbyopia treatments.
Over the past 7 days, AlphAI's AI scored 13 news stories mentioning VTRS (Viatris Inc). Coverage has skewed bullish: 7 bullish, 5 neutral, and 1 bearish.
Recent VTRS coverage spans financial news, earnings and mergers & acquisitions.
Modest guidance lift may not offset margin pressure and high debt, likely limiting upside.
Cash acquisition of a pain-focused portfolio is likely credit-neutral to modestly dilutive depending on funding, with near-term focus on integration and pipeline contribution.
The approval adds a novel ophthalmic drug to Viatris' portfolio, potentially expanding revenue and market share in the presbyopia space.
Viatris will fund a cash acquisition, reducing its cash balance and increasing leverage.
Earnings beat provides modest upside.
AlphAI scores every news story that mentions VTRS with an AI model for sentiment and relevance, and aggregates insider trades from Viatris Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Viatris (VTRS) and Eli Lilly (LLY) raised 2026 sales forecasts. Lilly increased its revenue forecast to $91.5B, while Viatris raised its forecast to $14.75B. Lilly's growth is driven by Mounjaro and Zepbound, while Viatris focuses on generics and potential blockbuster drugs. Lilly has higher margins and lower debt, but Viatris trades at a lower valuation.
2 min readIn October 2026, The Pharma Letter reported 12 M&A deals, including four worth over $1 billion. Shionogi (TYO: 4507) acquired IntraBio for $2 billion. Viatris (Nasdaq: VTRS) agreed to buy Pacira BioSciences (Nasdaq: PCRX) for $1.65 billion. Ferring Pharmaceuticals agreed to pay up to $1.38 billion for Gameto. Merck KGaA (ETR: MRK) acquired Silence Therapeutics (Nasdaq: SLN) for about $1.3 billion.
2 min readThe FDA approved phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) for presbyopia in October 2026. The drug reduces pupil size via a sympatholytic mechanism, avoiding ciliary muscle engagement. Clinical trials showed 27.2% of patients gained near vision without losing distance vision. Experts discuss its unique mechanism and potential patient benefits compared to other presbyopia treatments.
3 min readViatris Inc. (VTRS) has launched a tender offer to acquire all shares of Pacira BioSciences, Inc. (PCRX) for $36.50 per share in cash. The offer is part of a merger agreement, with Pacira's board recommending shareholders accept the deal. The offer expires on Nov. 16, 2026, unless extended or terminated.
2 min readMastercard (MA), Cheniere Energy (LNG), and Viatris (VTRS) reached 52-week highs. MA rose 4% post-Q3 earnings, exceeding estimates with $9.81B revenue and $5.28 EPS. LNG surged 7% with $6.17B revenue and $5.65 EPS, driven by LNG export market momentum. VTRS gained 2% on positive catalysts and financial performance.
2 min readPacira Pharmaceuticals (PCRX) reports Q3 earnings, with analysts expecting $0.73 EPS on $182.9M revenue. The company is nearing a $1.65B acquisition by Viatris (VTRS). Exparel's performance and pipeline progress on PCRX-201 are key focuses. The stock trades near the acquisition price, with a mean target of $33.57.
2 min readUS women face shortages of estrogen patches, injectables, and vaginal creams due to surging demand. The FDA has been working with manufacturers to boost supplies since September. Companies like Viatris, Amneal, and Cost Plus Drugs report increased demand and production efforts. Shortages may be exacerbated by women switching from scarce patches to alternatives. Multiple manufacturers, including Hikma, American Regent, and Teva, are affected.
2 min readPiper Sandler raised Viatris's (VTRS) price target to $14, citing multiple expansion for large-cap biopharma companies. VTRS shares are up 54% year-to-date, despite bearish retail sentiment. The article also mentions XOM and BTE reaching 52-week highs.
1 min readViatris Inc. voluntarily recalled 21,620 bottles of its telmisartan and amlodipine blood pressure medication due to potential excess telmisartan, according to the FDA. The class III recall affects specific lot codes with expiration dates in October and November. The FDA advises patients not to stop taking the medication abruptly.
1 min readPiper Sandler raised its price target for Viatris to $14 from $13. The stock has a 5-day change of $18.00, a 1st Jan change of -2.60%, and a 1-year change of +44.58%. JPMorgan previously adjusted its target to $20 from $18.
1 min read
